J. Goldman & CO LP Bridge Bio Pharma, Inc. Transaction History
J. Goldman & CO LP
- $3.21 Billion
- Q3 2024
A detailed history of J. Goldman & CO LP transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 40,500 shares of BBIO stock, worth $1.39 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
40,500Holding current value
$1.39 Million% of portfolio
0.03%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BBIO
# of Institutions
294Shares Held
171MCall Options Held
10.4MPut Options Held
2.36M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY25.3MShares$864 Million35.94% of portfolio
-
Viking Global Investors LP25.1MShares$859 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$486 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$426 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$208 Million63.58% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $5.07B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...